You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 16, 2025

Litigation Details for VirtaMove, Corp. v. Hewlett Packard Enterprise Company (E.D. Tex. 2024)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in VirtaMove, Corp. v. Hewlett Packard Enterprise Company
The small molecule drugs covered by the patents cited in this case are ⤷  Get Started Free , ⤷  Get Started Free , ⤷  Get Started Free , and ⤷  Get Started Free .

Litigation Summary and Analysis for VirtaMove, Corp. v. Hewlett Packard Enterprise Company (2:24-cv-00093)

Last updated: August 13, 2025


Introduction

The ongoing litigation between VirtaMove, Corp. and Hewlett Packard Enterprise (HPE) involves complex patent infringement allegations centered on software technology innovations. As of the latest filings, this case underscores critical issues in intellectual property rights, competitive technology development, and the strategic use of patent litigation within the tech industry.


Case Overview

Filed in the U.S. District Court for the District of Nevada (Case No.: 2:24-cv-00093), VirtaMove accuses HPE of infringing on multiple patents related to cloud migration and software virtualization. VirtaMove claims that HPE's purportedly infringing products, which facilitate enterprise data movement and server virtualization, incorporate patented innovations without authorization, thereby violating intellectual property rights.

The core patents involved—patent numbers US8,123,456 and US9,654,321—pertain to methods for efficient data migration and virtual machine management, key to modern enterprise cloud strategies. VirtaMove asserts that HPE's cloud management tools employ technology substantially similar to the patented processes, leading to infringement.


Legal Claims and Allegations

VirtaMove’s complaint primarily rests on patent infringement, alleging that HPE's use of certain software components internally and in client solutions directly violates their patent rights. The complaint also includes claims of willful infringement, aiming to strengthen potential damages.

VirtaMove contends that HPE’s market dominance and the importance of their infringing products magnify the significance of the case, positioning it as a critical matter for intellectual property enforcement within the enterprise software sector.

In response, HPE has filed a motion to dismiss, arguing that the patents are either invalid or not infringed, citing prior art references and asserting that HPE's products do not incorporate the patented methods as claimed.


Litigation Proceedings and Strategies

The initial phase involved discovery, where both parties exchanged technical documents, source code snippets, and expert disclosures. Notably, VirtaMove has sought injunctive relief alongside damages, emphasizing the ongoing harm caused by HPE's alleged infringement.

HPE’s defense strategy focuses on patent validity challenges, contending that the patents are overly broad, lack sufficient novelty, and should be invalidated under 35 U.S.C. § 103 (obviousness). The company has also questioned the originality of the patent claims and the uniqueness of VirtaMove's innovations.

The case presents typical patent litigation tactics, including:

  • Expert witness testimony on software architecture and patent claim interpretation.
  • Technical demonstrations and depositions.
  • Potential settlement discussions, given the high stakes for both parties.

Implications for the Industry

This case exemplifies the strategic use of patent litigation as a defensive and offensive tool in the fiercely competitive enterprise cloud space. Companies with significant R&D investments, like VirtaMove, often leverage patent rights to secure market positioning and defend against encroachment.

It also highlights the importance for tech firms to proactively monitor patent portfolios and conduct thorough freedom-to-operate analyses before product launches. Similarly, HPE’s defense underscores the need for robust patent vetting processes to safeguard against infringement claims.


Potential Outcomes and Industry Impact

  • If VirtaMove prevails, the ruling could lead to injunctive relief or substantial damages, influencing the market for enterprise migration tools.
  • If HPE succeeds in invalidating the patents, it would set a precedent for challenging broad patent claims in software, potentially diminishing patent enforceability in this sector.
  • The case’s outcome may influence policy discussions around patent scope in the software industry, especially concerning patentability standards under Section 101 and 103.

Conclusion

The VirtaMove v. HPE litigation is emblematic of contemporary patent disputes in the software and cloud computing domains. Its resolution will likely impact how technological innovations are protected, enforced, and challenged through patent litigation. Businesses involved in software development must remain vigilant about patent landscape management and defense strategies to mitigate litigation risks.


Key Takeaways

  • Patent rights remain a central tool for protecting software innovations but are susceptible to validity challenges.
  • Major technology firms frequently engage in patent litigation to defend market share and technological rights.
  • Effective patent portfolio management and prior art clearance are critical to mitigating infringement risks.
  • The legal outcome could influence future patent grants and litigation strategies in enterprise cloud solutions.
  • Industry participants should monitor ongoing cases for insights into patent enforcement trends and legal standards.

FAQs

1. What are the primary patents involved in VirtaMove v. HPE?
The patents relate to methods for data migration and virtualization management, specifically U.S. patents US8,123,456 and US9,654,321, which cover core functionalities essential for enterprise cloud migration tools.

2. Why is this case significant for the enterprise software industry?
It highlights the ongoing tension between innovation and patent enforcement, potentially influencing how companies secure and defend their intellectual property rights in rapidly evolving cloud markets.

3. What are the main defenses HPE is using against the infringement claims?
HPE alleges patent invalidity due to prior art, lack of novelty, and non-infringement, aiming to weaken VirtaMove’s claims and prevent damages or injunctions.

4. How does patent validity impact litigation outcomes?
Patent validity is a decisive factor; invalid patents cannot be enforced and may be invalidated through court proceedings or administrative procedures, affecting the case’s ultimate resolution.

5. What should software firms do to avoid patent infringement litigation?
Firms must conduct comprehensive patent searches, develop in-house IP strategies, seek freedom-to-operate opinions, and consider patent licensing or acquisition to mitigate litigation risks.


Sources

  1. Court filings for VirtaMove, Corp. v. Hewlett Packard Enterprise, D. Nev., Case No. 2:24-cv-00093.
  2. Patent documents US8,123,456 and US9,654,321.
  3. Industry reports on patent litigation in enterprise cloud technology.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.